drugset / Trial / NCT03769090

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

NCT03769090

Phase 3 Completed 3132 enrolled Bond Avillion 2 Development LP
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.

Timeline

Start
2018-12-13
Primary completion
2021-08-19
Completion
2022-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 80 ug Inhaled
Subject Budesonide Small molecule 160 ug Inhaled
Comparator Salbutamol Unknown 180 ug Inhaled

Indications